Ziakas A, Gavrilidis S, Giannoglou G, Souliou E, Gemitzis K, Kalampalika D, Vayona M Arvanitidou, Pidonia I, Parharidis G, Louridas G
1st Cardiology Department, AHEPA, University Hospital, Thessaloniki, Greece.
Angiology. 2006 May-Jun;57(3):283-93. doi: 10.1177/000331970605700304.
Plasma fibrinogen, C-reactive protein (CRP), and interleukin-6 (IL-6) levels in patients with acute myocardial infarction (AMI) receiving thrombolysis have been related to prognosis. The aim of this study was to investigate the time course of plasma fibrinogen, CRP, and IL-6 levels during the in-hospital phase in patients with AMI receiving thrombolysis, and their relationship to in-hospital and prognosis after 12-months follow-up. In 40 patients presenting with AMI within 6 hours of symptom onset and treated with thrombolysis, plasma fibrinogen, CRP, and IL-6 levels were measured on admission and after 6, 12, 24, 48, and 72 hours; 7 days; and 6 months. Patients with other diseases that can alter fibrinogen, CRP, or IL-6 levels were excluded. Patients had a clinical follow-up at 6 and 12 months, and the following cardiac events were recorded: cardiac death, recurrent angina, recurrent AMI, and heart failure. Plasma fibrinogen concentrations decreased significantly (p <0.01 vs admission levels) at 12 hours (425 +/-94 vs 322 +/-132 mg/dL), started to increase at 24 hours, reached peak value at 72 hours (602 +/-209 mg/dL), remained elevated at 7 days, and were back to admission levels at 6 months (375 +/-79 mg/dL). CRP levels increased significantly at 12 hours (0.73 +/-0.43 vs 0.23 +/-0.11 mg/dL, p <0.01), reached peak value at 72 hours (7.66 +/-3.28 mg/dL), decreased significantly on day 7 (2.32 +/-1.17 mg/dL), and at 6 months were within normal limits (0.49 +/-0.29 mg/dL). IL-6 levels increased significantly at 6 hours (14.03 +/-8.13 vs 6.37 +/-3.88 pg/mL, p <0.05), reached peak value at 24 hours (59.49 +/-23.57 pg/mL), started to decrease at 48 hours, and at 6 months were within normal limits (2.25 +/-1.24 pg/mL). During the in-hospital phase 33 patients had an uneventful course and 7 patients had complications (3 post-AMI angina; 4 heart failure). During the 12-month follow-up period 28 patients had an uneventful course, and 12 patients had complications (1 cardiac death, 5 recurrent angina, 2 recurrent AMI, and 4 heart failure). Regarding the in-hospital prognosis, fibrinogen, CRP, and IL-6 levels were significantly higher (p <0.05) in patients with complications from 48 to 72 hours, from 12 hours until day 7, and from 6 hours until day 7, respectively. During the 12-month follow-up period fibrinogen, CRP, and IL-6 levels were significantly higher in patients with complications (at 48, 24, and 24 hours, respectively) only in the subgroup of patients who had complications within the first 6 months following AMI. Multivariate analysis showed that CRP at 48 hours was the most important factor related to in-hospital prognosis (p = 0.02), and ejection fraction followed by CRP at 24 hours (p = 0.02) to 6-month prognosis (p = 0.018). Fibrinogen, CRP, and IL-6 levels alter in patients with AMI receiving thrombolysis, and are related both to in-hospital and to 6-month follow-up prognosis.
接受溶栓治疗的急性心肌梗死(AMI)患者的血浆纤维蛋白原、C反应蛋白(CRP)和白细胞介素-6(IL-6)水平与预后相关。本研究旨在调查接受溶栓治疗的AMI患者在住院期间血浆纤维蛋白原、CRP和IL-6水平的时间变化过程,以及它们与住院情况和12个月随访后的预后的关系。在40例症状发作后6小时内出现AMI并接受溶栓治疗的患者中,于入院时以及6、12、24、48和72小时;7天;以及6个月时测量血浆纤维蛋白原、CRP和IL-6水平。排除患有其他可改变纤维蛋白原、CRP或IL-6水平疾病的患者。患者在6个月和12个月时进行临床随访,并记录以下心脏事件:心源性死亡、复发性心绞痛、复发性AMI和心力衰竭。血浆纤维蛋白原浓度在12小时时显著降低(与入院水平相比,p<0.01)(425±94 vs 322±132 mg/dL),在24小时开始升高,在72小时达到峰值(602±209 mg/dL),在7天时仍保持升高,在6个月时恢复到入院水平(375±79 mg/dL)。CRP水平在12小时时显著升高(0.73±0.43 vs 0.23±0.11 mg/dL,p<0.01),在72小时达到峰值(7.66±3.28 mg/dL),在第7天显著降低(2.32±1.17 mg/dL),在6个月时处于正常范围内(0.49±0.29 mg/dL)。IL-6水平在6小时时显著升高(14.03±8.13 vs 6.37±3.88 pg/mL,p<0.05),在24小时达到峰值(59.49±23.57 pg/mL),在48小时开始降低,在6个月时处于正常范围内(2.25±1.24 pg/mL)。在住院期间,33例患者病情平稳,7例患者出现并发症(3例AMI后心绞痛;4例心力衰竭)。在12个月的随访期内,28例患者病情平稳,12例患者出现并发症(1例心源性死亡,5例复发性心绞痛,2例复发性AMI,4例心力衰竭)。关于住院预后,有并发症的患者在48至72小时、从12小时至第7天、从6小时至第7天的纤维蛋白原、CRP和IL-6水平分别显著更高(p<0.05)。在12个月的随访期内,仅在AMI后前6个月内出现并发症的患者亚组中,有并发症的患者的纤维蛋白原、CRP和IL-6水平分别在48、24和24小时显著更高。多因素分析显示,48小时时的CRP是与住院预后相关的最重要因素(p = 0.02),射血分数其次,24小时时的CRP对6个月预后有影响(p = 0.02)(p = 0.018)。接受溶栓治疗的AMI患者的纤维蛋白原、CRP和IL-6水平会发生变化,并且与住院情况和6个月随访预后均相关。